🇺🇸 FDA
Pipeline program

Pegcetacoplan

APL2-DGF-318

Phase 3 small_molecule active

Quick answer

Pegcetacoplan for Delayed Graft Function is a Phase 3 program (small_molecule) at Apellis Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Apellis Pharmaceuticals
Indication
Delayed Graft Function
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials